Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Unit of Rheumatology, Policlinico Le Scotte, University of Siena, Siena, Italy.
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1051-8. doi: 10.1177/039463200902200421.
Recurrences develop in up to 20-50% of patients with acute pericarditis. Although different causes of recurrent pericarditis have been identified, the etiology remains obscure in most cases which are therefore labelled as idiopathic. Autoinflammatory syndromes include familial Mediterranean fever (FMF), due to mutations in the MEFV gene, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS), due to mutations in the TNFRSF1A gene. Recurrent pericarditis is a common feature of both conditions, but it rarely occurs alone. Colchicine is the standard treatment for FMF, while patients with TRAPS do not respond to colchicine therapy, but are responsive to corticosteroids. Based on the proven efficacy of colchicine in preventing polyserositis in FMF, colchicine has been proposed for the treatment of recurrent pericarditis and is able to decrease the recurrence rate. Our aim was to investigate the possible involvement of TNFRSF1A mutations in a group of patients with idiopathic recurrent pericarditis who were refractory to colchicine treatment. Thirty consecutive patients (17 males, 13 females) diagnosed with idiopathic recurrent pericarditis, who were characterized by a poor response to colchicine treatment, were enrolled in the study. Mutations of the TNFRSF1A gene were searched for by amplifying, using polymerase chain reaction (PCR), genomic DNA, and direct sequencing. TNFRSF1A mutations were found in 4 of the 30 patients. None of these 4 patients had a family history of recurrent inflammatory syndromes or history of pericarditis. One of the 4 patients had a novel heterozygous deletion (DeltaY103-R104) and three patients carried a heterozygous low-penetrance R92Q mutation. Our data suggest that TRAPS should be kept in mind in the differential diagnosis of recurrent pericarditis, and mutation analysis of the TNFRSF1A gene should be considered, in addition to MEFV analysis, in patients of Mediterranean origin. A poor response to colchicine treatment and/or a steroid-dependence may be the clue to investigate TNFRSF1A mutations in patients with idiopathic recurrent pericarditis.
复发性心包炎可发生于多达 20-50%的急性心包炎患者中。虽然已经确定了复发性心包炎的不同病因,但在大多数情况下病因仍不清楚,因此被归类为特发性。自身炎症性疾病包括家族性地中海热(FMF),由 MEFV 基因突变引起,以及肿瘤坏死因子受体相关周期性综合征(TRAPS),由 TNFRSF1A 基因突变引起。复发性心包炎是这两种疾病的共同特征,但很少单独发生。秋水仙碱是 FMF 的标准治疗方法,而 TRAPS 患者对秋水仙碱治疗无反应,但对皮质类固醇有反应。基于秋水仙碱在预防 FMF 多浆膜炎方面的疗效已被证实,因此有人提议用秋水仙碱治疗复发性心包炎,并能降低复发率。我们的目的是研究 TNFRSF1A 基因突变是否可能参与一组对秋水仙碱治疗反应不佳的特发性复发性心包炎患者。连续 30 例(男 17 例,女 13 例)特发性复发性心包炎患者被纳入研究,这些患者的特点是对秋水仙碱治疗反应不佳。通过聚合酶链反应(PCR)扩增、基因组 DNA 并直接测序,寻找 TNFRSF1A 基因突变。在 30 例患者中发现了 4 例 TNFRSF1A 基因突变。这 4 例患者均无复发性炎症综合征家族史或心包炎病史。其中 1 例患者存在新的杂合缺失(DeltaY103-R104),3 例患者携带杂合低外显率 R92Q 突变。我们的数据表明,在复发性心包炎的鉴别诊断中应考虑 TRAPS,并且除了 MEFV 分析外,还应考虑 TNFRSF1A 基因突变分析,特别是在来自地中海地区的患者中。对秋水仙碱治疗反应不佳和/或对类固醇依赖可能是提示特发性复发性心包炎患者进行 TNFRSF1A 基因突变分析的线索。